-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GE's full-year revenue fell 16 percent on Jan. 27, according to the Securities and Exchange Commission.
sub-business section, the healthcare business generated revenue of $18 billion, down 10 percent from $1.99 billion in 2019, and a profit of $3.06 billion, down 18 percent from $3.74 billion in 2019.
's power business achieved revenue of $17.59 billion, down 6% YoY, and profit of $270 million, down 6% YoY, while its renewable energy business achieved revenue of $15.67 billion, up 2% YoY, and profit of $715 million, up 10% YoY.
aviation business reported revenue of $22.04 billion, down 33% year-on-year and profit of $1.23 billion, down 82% year-on-year.
GE said in its report that its ventilator production capacity had tripled in support of the fight against the outbreak and that other techniques had been used to diagnose and treat new coronary pneumonia.
supported 3,900 employees and their families through the GE Employee Relief Fund and supported global and community health and disaster relief efforts through the GE Foundation.
understood that from a product perspective, GE Healthcare will launch more than 40 new medical products in 2020, and from a regional perspective, GE Healthcare will see strong growth in Europe and China in 2020, with revenues in China exceeding $2 billion, up 11% in the first quarter alone, and U.S. revenues exceeding $6.5 billion, up 2% year-on-year, including U.S. government respirator orders.
reported modest growth for the full year, and Philips also reported full-year results.
sales reached 6,001 million euros ($47,192 million) in the fourth quarter, up 7 percent from a year earlier, according to Global.com.
net profit for the quarter reached 607 million euros (about 4,773 million yuan), up 9.2% year-on-year.
By business, Philips' diagnostic and therapeutic business sales in the fourth quarter of 2020 amounted to EUR 2,458 million (RMB19,330 million), the Internet Care business to EUR 1,581 million (RMB12,197 million) and personal health sales to EUR 1,824 million (RMB14,344 million).
, Philips' full-year 2020 sales reached EUR 19,535 million (RMB153.625 billion), up 3% year-on-year.
full-year net profit reached 1,195 million euros (9,398 million yuan), up 1.9 percent from a year earlier.
January, Philips also announced it would buy Capsule Technologies from investment firm Francisco Partners for $635m in cash.
deal is expected to close in the first quarter of 2021, and Capsule's leadership team and approximately 300 employees will join the Philips Connected Care business unit.
, the latest results of well-known multinational arms companies such as Johnson and Johnson and Medtron have also been announced.
. Johnson and Johnson's third-quarter 2020 results far exceeded expectations, with third-quarter sales rising to $21,082 million from $20,729 million a year earlier, according to the company.
, the medical device business had sales of $6.15 billion.
net profit rose to $3,554 million from $1,753 million a year earlier, up 102.7 percent from a year earlier.
Medtron announces second-quarter results for fiscal 2021.
revenue for the reporting period was $7.647 billion, compared with $7.706 billion in the same period last year.
net profit was $494 million, compared with $1.371 billion a year earlier.
by business, the revenue of the minimally invasive treatment group was $2.285 billion, up 6.7% YoY, the cardiovascular group was $2.725 billion, down 4.6% YoY, the recovery treatment group was $2,063 million, down 2.3% YoY, and the diabetes group's revenue was $574 million, down 3.7% YoY.